ClinicalTrials.gg
RecruitingNCT07286149Updated Oct 1, 2026

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

A Phase 1/2 interventional study of MK-1084 and Patritumab deruxtecan in Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme LLC. Recruiting at 29 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 1, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lung Neoplasms by Merck & Co., Inc — 4 open to participants now, 8 under way, 3 of them phase 3. Lung Neoplasms · Merck & Co., Inc.

Planned enrollment
8th of 12
140 · median 188
Started
2026
the only one that year
Phase 1/2
3 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Lung Neoplasms by Merck & Co., Inc, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 1/2, and was the 12th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

4 of the 12 studies in Lung Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lung Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:

  • About the safety of MK-1084 and if people tolerate it when taken with other treatments
  • How many people have the cancer respond (get smaller or go away) to the treatments
Read the detailed description

This is a substudy of the master protocol MK-3475-U01 (KEYMAKER-U01) - NCT04165798.

Per amendment 3, the MK-1084 + Cetuximab arm was discontinued.

03

Conditions studied

  • Lung Neoplasm Malignant

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has or cytologically confirmed diagnosis of advanced or non-squamous non-small cell lung cancer (NSCLC)
  • Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations
  • Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 ()/programmed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy
  • Has provided tumor tissue for biomarker analysis from an or a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Participants with (HIV) infection must have well-controlled HIV on antiretroviral therapy (ART) per protocol

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has evidence of any
  • Has uncontrolled or significant cardiovascular disorder or cerebrovascular disease prior to allocation/randomization
  • Has one or more of the following ophthalmological conditions: a) corneal disease b) history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received a live or within 30 days before the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use or current ILD, or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    MK-1084 + Patritumab deruxtecan (HER3-DXd)

    Participants will receive MK-1084 and HER3-DXd until discontinuation due to toxicity, adverse event (AE) or at the discretion of an investigator.

    Drug: MK-1084 · Biological: Patritumab deruxtecan · Drug: Rescue Medications

  • Experimental
    MK-1084 + Sacituzumab tirumotecan (Sac-TMT)

    Participants will receive MK-1084 and sac-TMT until discontinuation due to toxicity, AE or at the discretion of an investigator.

    Drug: MK-1084 · Biological: Sacituzumab tirumotecan · Drug: Rescue Medications

  • Experimental
    MK-1084 + Cetuximab

    Participants will receive MK-1084 and cetuximab until discontinuation due to toxicity, AE or at the discretion of an investigator. Per amendment 3, the MK-1084 + Cetuximab arm was discontinued.

    Drug: MK-1084 · Biological: Cetuximab

Interventions

  • DrugCalderasibStudies of CalderasibCalderasib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration

  • IV infusion

    Also known as: HER3-DXd, MK-1022, U3-1402

  • IV Infusion

    Also known as: Sac-TMT, MK-2870, SKB264

  • BiologicalCetuximab

    IV Infusion

    Also known as: C225, Erbitux

  • DrugRescue Medications

    Participants receive rescue medication at the investigator's discretion for prevention of nausea and vomiting, per approved product label. Recommended rescue medications are histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent), 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist and corticosteroid.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

    DLT will be defined as any drug-related AE observed during the DLT evaluation period (up to 42 days) that results in a change to a given dose or a delay in initiating the next treatment.

    Time frame: Up to 42 days

  2. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 63 months

  3. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 62 months

  4. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 63 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 63 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 71 months

  3. Area Under the Curve From Time 0 to the End of the Dosing Interval (AUC tau)

    Blood samples will be collected at multiple time points to estimate AUC tau.

    Time frame: Predose and at designated time points post-dose (up to approximately 63 months)

  4. Maximum Plasma Concentration (Cmax)

    Blood samples will be collected at multiple time points to estimate Cmax.

    Time frame: Predose and at designated time points post-dose (up to approximately 63 months)

  5. Minimum Observed Concentration (Ctrough)

    Blood samples will be collected at multiple time points to estimate Ctrough.

    Time frame: Predose and at designated time points post-dose (up to approximately 63 months)

07

Study locations

29 of 29 sites recruiting
  • Clermont Oncology Center ( Site 0041)
    Clermont, Florida 34711, United States
    Recruiting
    • Study Coordinator · Contact386-538-3169
  • University of Illinois Hospital & Health Sciences System ( Site 0044)
    Chicago, Illinois 60612, United States
    Recruiting
    • Study Coordinator · Contact312-996-9272
  • Providence Portland Medical Center ( Site 0043)
    Portland, Oregon 97213, United States
    Recruiting
    • Study Coordinator · Contact503-215-1979
  • Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)
    Portland, Oregon 97225, United States
    Recruiting
    • Study Coordinator · Contact503-215-1979
  • Hospital São Lucas da PUCRS ( Site 0283)
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    Recruiting
    • Study Coordinator · Contact+555133203000
  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)
    Barretos, São Paulo 14784-400, Brazil
    Recruiting
    • Study Coordinator · Contact+551733216637
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Study Coordinator · Contact+551732015000
  • Hospital Paulistano ( Site 0280)
    São Paulo, São Paulo 01321001, Brazil
    Recruiting
    • Study Coordinator · Contact55 11 31411083
  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)
    Santiago, Region M. de Santiago 7500653, Chile
    Recruiting
    • Study Coordinator · Contact+56991612199
  • Fundación Arturo López Pérez ( Site 0161)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • Bradfordhill ( Site 0160)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Guangdong Provincial People s Hospital ( Site 0300)
    Guangzhou, Guangdong 510120, China
    Recruiting
    • Study Coordinator · Contact02083525210
  • Yunnan Province Cancer Hospital ( Site 0302)
    Kunming, Yunnan 650107, China
    Recruiting
    • Study Coordinator · Contact+8687168189037
  • UniversitaetsklInikum Tuebingen ( Site 0192)
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Study Coordinator · Contact+4970712982795
  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)
    Athens, Attica 115 27, Greece
    Recruiting
    • Study Coordinator · Contact+30210 7763100
  • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)
    Athens, Attica 115 28, Greece
    Recruiting
    • Study Coordinator · Contact+302132162543
  • Papageorgiou General Hospital of Thessaloniki ( Site 0206)
    N.Efkarpia, Thessaloniki 564 29, Greece
    Recruiting
    • Study Coordinator · Contact+302313323959
  • Queen Mary Hospital ( Site 0230)
    Hong Kong, 000000, Hong Kong
    Recruiting
    • Study Coordinator · Contact+85222551727
  • Hong Kong United Oncology Centre ( Site 0232)
    Jordan, 000000, Hong Kong
    Recruiting
    • Study Coordinator · Contact+852 5508 7858
  • Prince of Wales Hospital ( Site 0231)
    Shatin, Hong Kong
    Recruiting
    • Study Coordinator · Contact+852 3505 1202
  • Shaare Zedek Medical Center ( Site 0186)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+97226555999
  • Meir Medical Center ( Site 0181)
    Kfar Saba, 4428164, Israel
    Recruiting
    • Study Coordinator · Contact+97297472555
  • Sheba Medical Center ( Site 0180)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+97235303030
  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)
    Meldola, Forli-Cesena 47014, Italy
    Recruiting
    • Study Coordinator · Contact393487469100
  • Severance Hospital, Yonsei University Health System ( Site 0080)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+82222280880
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
    Hospitalet, Barcelona 08908, Spain
    Recruiting
    • Study Coordinator · Contact0034932607744
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 0091)
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
    • Study Coordinator · Contact+34914521987
  • Hospital Clinic de Barcelona ( Site 0092)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact34 932275402
  • Hospital Universitario Virgen Macarena ( Site 0093)
    Seville, 41009, Spain
    Recruiting
    • Study Coordinator · Contact+34 671560092
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2029, 39 months after the start.

Of 79 industry-sponsored phase 1/2 interventional studies under Lung Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 82. This study's planned 39 months is below that.

Counting every sponsor, half of 157 studies reached it within 54 months; a quarter within 39 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 16, 2025
StartActual
Apr 30, 2026
Primary completionEst.
Aug 17, 2029
CompletionEst.
Apr 13, 2032
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 China, 1 Chile)
  • Yunnan Province Cancer Hospital ( Site 0302) · Kunming, China
  • Fundación Arturo López Pérez ( Site 0161) · Santiago, Chile
Show 1 removed
  • FALP ( Site 0161) · Santiago, Chile
across 2 updates, Sep 28, 2026 – Oct 1, 2026
Show all 2 updates
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Fundación Arturo López Pérez ( Site 0161) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0161) · Santiago, Chile
  2. Sep 28, 2026
    1 site added
    Show site
    • Yunnan Province Cancer Hospital ( Site 0302) · Kunming, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07286149
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Apr 30, 2026
Primary completion
Aug 17, 2029 (estimated)
Completion
Apr 13, 2032 (estimated)
Last update
Oct 1, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion